Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease

Thorax

Volumn 68, Issue 7, 2013, Pages 670-676

  Duvoix, Annelyse ^a   Dickens, Jenny ^a   Haq, Imran ^a   Mannino, David ^b   Miller, Bruce ^c   Tal Singer, Ruth ^c   Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DILMAPIMOD; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOSMAPIMOD; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PREDNISOLONE;

ABDOMINAL AORTA ANEURYSM; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; DISEASE SEVERITY; EMPHYSEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC POLYMORPHISM; HUMAN; ISCHEMIC HEART DISEASE; LUNG FUNCTION; METABOLIC SYNDROME X; MORTALITY; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BIOMARKER; COPD; FIBRINOGEN; INFLAMMATION;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; FIBRINOGEN; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84879412209     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201871     Document Type: Article

References (68)

1. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-82. (Pubitemid 40631293)
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55. (Pubitemid 47403272)
3. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed-urgently. Am J Respir Crit Care Med 2010;182:863-4.
4. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
5. Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
6. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007;62:595-601. (Pubitemid 47056886)
7. http://www.copdfoundation.org/PressRoom/ArticlesPressReleases/News/187. aspx (accessed 2 Feb 2012).
8. Gordon A, Koj A. The Acute Phase Response to Injury and Infection. Amsterdam: Elsevier, 1985.
9. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. (Pubitemid 29084777)
10. Mackiewicz A, Speroff T, Ganapathi MK, et al. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032-7.
11. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-11. (Pubitemid 32971649)
12. Valvi D, Mannino DM, Mullerova H, et al. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis 2012;7:173-82.
13. Engstrom G, Segelstorm N, Ekberg-Aronsson M, et al. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax 2009;64:211-15.
14. Kalhan R, Tran BT, Colangelo LA, et al. Systemic inflammation in young adults is associated with abnormal lung function in middle age. PLoS One 2010;5:e11431.
15. Jiang R, Burke GL, Enright PL, et al. Inflammatory markers and longitudinal lung function decline in the elderly. Am J Epidemiol 2008;168:602-10.
16. Alessandri C, Basili S, Violi F, et al. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost 1994;72:343-6. (Pubitemid 24280769)
17. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:1211-18.
18. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-62. (Pubitemid 36776358)
19. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80. (Pubitemid 38901515)
20. Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010;11:63.
21. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809. (Pubitemid 41434626)
22. Mannino DM, Valvi D, Mullerova H, et al. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. COPD. Published Online First: 11 April 2012. doi:10.3109/15412555.2012.668249.
23. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004. (Pubitemid 41507533)
24. Higashimoto Y, Iwata T, Okada M, et al. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009;103:1231-8.
25. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-92.
26. Papaioannou AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med 2010;104:275-82.
27. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
28. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-15. (Pubitemid 30601465)
29. Groenewegen KH, Postma DS, Hop WC, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008;133:350-7. (Pubitemid 351272391)
30. Mackay AJ, Donaldson GC, Patel AR, et al. Utility of the COPD Assessment Test (CAT) to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med 2012;185:1218-24.
31. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004;23:685-91. (Pubitemid 38618136)
32. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23. (Pubitemid 33124148)
33. Polatli M, Cakir A, Cildag O, et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008;26:97-102.
34. Saldias PF, Diaz PO, Dreyse DJ, et al. [Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations] Revista medica de Chile 2011;140:10-18.
35. Koutsokera A, Kiropoulos TS, Nikoulis DJ, et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med 2009;103:919-26.
36. Valipour A, Schreder M, Wolzt M, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008;115:225-32.
37. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996;348:567-72. (Pubitemid 26283887)
38. Fowkes FG, Anandan CL, Lee AJ, et al. Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease. J Vasc Surg 2006;43:474-80. (Pubitemid 43332728)
39. Castagna O, Boussuges A, Nussbaum E, et al. Peripheral arterial disease: an underestimated aetiology of exercise intolerance in chronic obstructive pulmonary disease patients. Eur J Cardiovasc Prev Rehabil 2008;15:270-7.
40. Blum A, Simsolo C, Sirchan R, et al. 'Obesity paradox' in chronic obstructive pulmonary disease. Isr Med Assoc J 2011;13:672-5.
41. Maksimovic M, Vlajinac H, Radak D, et al. Relationship between high-sensitivity C-reactive protein and risk factors in patients with peripheral arterial disease: a cross-sectional study. Angiology. Published Online First: 11 April 2012. doi:10. 1177/0003319712440303.
42. McDermott MM, Guralnik JM, Corsi A, et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 2005;150:276-81. (Pubitemid 41116253)
43. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009;136:1039-46.
44. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012;106:522-30.
45. Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008;177:743-51. (Pubitemid 351490561)
46. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011;140:331-42.
47. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet 2009;10:23.
48. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.
49. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2011;52:416-24.
50. Kunter E, Ilvan A, Ozmen N, et al. Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation. Respiration 2008;75:145-54. (Pubitemid 351363867)
51. Barnes NC, Pavord ID, Maden C, et al. Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD. ERS 19th Annual Congress; 12th - 16th Sept 2009, Vienna. [Abstract no. E3144].
52. Dentener MA, Creutzberg EC, Pennings HJ, et al. Effect of infliximab on local and systemic inflammation in chronic obstructive pulmonary disease: a pilot study. Respiration 2008;76:275-82.
53. Kaczmarek P, Sladek K, Skucha W, et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn 2010;120:11-17.
54. Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102:1634-8.
55. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-75. (Pubitemid 41507542)
56. Kumakura H, Kanai H, Aizaki M, et al. The influence of the obesity paradox and chronic kidney disease on long-term survival in a Japanese cohort with peripheral arterial disease. J Vasc Surg 2010;52:110-17.
57. Technology Strategy Board. Driving innovation. http://www.innovateuk.org/ -assets/0511/press-release-stratmed-results-19may11.pdf (accessed 2 Feb 2012).
58. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003;168:351-8. (Pubitemid 36703335)
59. Mora S, Cook N, Buring JE, et al. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007;116:2110-18. (Pubitemid 350060348)
60. de Maat MP, Bladbjerg EM, Hjelmborg JB, et al. Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 2004;24: 2168-73. (Pubitemid 39482447)
61. Yang Q, Tofler GH, Cupples LA, et al. A genome-wide search for genes affecting circulating fibrinogen levels in the Framingham Heart Study. Thromb Res 2003;110:57-64. (Pubitemid 36859856)
62. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma levels. Blood 2005;106:4176-83. (Pubitemid 41775924)
63. Renda T, Baraldo S, Pelaia G, et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-9.
64. Mercer BA, D'Armiento JM. Emerging role of MAP kinase pathways as therapeutic targets in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:137-50.
65. Walter RE, Wilk JB, Larson MG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008;133:19-25.
66. Lomas DA, Silverman EK, Edwards LD, et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-63.
67. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5. (Pubitemid 46203128)
68. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 Concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1187-92.